Regression of left ventricular hypertrophy and improved prognosis: Some HOPE now. . .or hype?

Circulation

Volumn 104, Issue 14, 2001, Pages 1582-1584

  Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Editorials; Hypertension; Hypertrophy; Prognosis; Trials

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LOSARTAN; PERINDOPRIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; ECHOGRAPHY; EDITORIAL; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0035797853     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/circ.104.14.1582     Document Type: Editorial

References (20)

1. Hypertensive heart disease: A complex syndrome or a hypertensive 'cardiomyopathy'?
2. Criteria for an informative trial of left ventricular hypertrophy regression
3. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies
4. Reversal of left ventricular hypertrophy in hypertensive patients: A metaanalysis of 109 treatment studies
5. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS)
6. The effect of weight reduction on left ventricular mass: A randomized controlled trial in young, overweight hypertensive patients
7. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin converting enzyme inhibitor, ramipril
8. Hypertension and the prothrombotic state
9. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy
10. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension
11. The role of rheological and haemostatic factors in hypertension
12. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives
13. Angiogenesis and hypertension
14. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension
15. Heart attack, stroke, diabetes, and hypertension in West Indians, Asians, and whites in Birmingham, England
16. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction
17. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive lipid-lowering treatment to prevent heart attack trial (ALHAT)
18. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study: Losartan intervention for endpoint reduction in hypertension
19. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial: ASCOT investigators